Navigation Links
Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application

SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that the South Korea Food and Drug Administration has approved Anesiva's investigational new drug application for Adlea(TM), the company's long-acting, site specific, non-opioid drug candidate in Phase 3 clinical development for the management of acute pain following orthopedic surgery. Anesiva plans to initiate a Phase 2 clinical trial of Adlea in patients undergoing arthroscopic shoulder surgery in South Korea this summer.

"We selected South Korea for this Adlea clinical trial because the standards of care in orthopedic surgery and the professional training of its clinicians are similar to those in the United States," said John McLaughlin, chief executive officer. "An important difference from U.S. clinical practice is that arthroscopic shoulder surgery patients in South Korea are routinely admitted to the hospital for two or more days following surgery. This extended hospitalization period will enable us to conduct longer and more detailed post-surgical safety and efficacy analyses than would be practical in the United States."

The planned study is a multicenter, randomized, double-blind, placebo- controlled, two-stage exploratory study to evaluate the safety, tolerability, efficacy and pharmacokinetics of a single dose of Adlea compared to placebo administered at the conclusion of arthroscopic shoulder surgery. The trial is designed to enroll 74 patients.

Adlea is currently in two pivotal Phase 3 trials in the U.S.: one in total knee replacement surgeries and one in bunionectomy surgeries. Top-line data from both trials are expected by year-end 2008. An additional Phase 2 Adlea trial is in progress in total hip replacement surgeries. These trials are among those intended to support a broad Adlea label indication for the management of acute pain following orthopedic surgery.

How Adlea May Address the Need for Long-Duration, Well-Tolerated Pain Relief

Adlea is a long-acting, non-opioid drug with the potential to provide pain relief for weeks to months after a single localized treatment. Its novel mechanism of action results in site-specific efficacy intended to avoid the unwanted side effects associated with systemically administered analgesic drugs such as opioids and NSAIDs.

Adlea is a highly purified form of capsaicin (derived from chili peppers) that acts primarily on TRPV-1 receptors residing on C-fiber neurons which transmit long-term pain by binding to and desensitizing these pain receptors. This leads to a prolonged, reversible and localized desensitization of the pain fibers. The drug generally has a short half-life of 1 to 2 hours, and is undetectable in the blood after 24 hours.

Adlea's short duration of systemic exposure relative to the longer duration of analgesia may offer a safe, additive treatment option in the management of post-surgical orthopedic pain, as well as pain due to moderate to severe osteoarthritis. In clinical trials to date, adverse events have been similar in patients receiving Adlea or placebo.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. Anesiva has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. In clinical trials, the most common adverse reactions to Zingo were redness (erythema), red dots (petechiae) and swelling (edema). The next product in Anesiva's pipeline, Adlea(TM), is currently in two pivotal Phase 3 clinical trials to support an indication for the management of acute pain following orthopedic surgery. Adlea has been shown to reduce pain after only a single administration for weeks to months in multiple settings in mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward- looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, and our regulatory approval strategy for Adlea. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's annual report on Form 10-K for the year ended December 31, 2007 and most recently quarterly report on Form 10-Q.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
2. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
3. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Anesiva Defines Regulatory Pathway for Adlea with FDA
6. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
7. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
10. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
11. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
Post Your Comments:
(Date:11/30/2015)... , Belgium , Nov. 30, 2015 ... sciences company focused on developing blood-based diagnostic tests for a ... the Company will present at the LD Micro Conference, which ... Los Angeles, CA. Attending from VolitionRx will be ... Scott Powell , Vice President of Investor Relations. ...
(Date:11/30/2015)... , November 30, 2015 Mexico Healthcare and ... Life Sciences Report 2015 . --> Pharmaboardroom releases its ... Latin America , a country of over ... a country of over 122 million people. --> It ... pharmaceuticals, or life sciences insights into the second largest pharma and ...
(Date:11/30/2015)... 2015 Sectra (STO: SECT ... entered into a multi-year agreement to provide Breast Imaging ... Kentucky Breast Care to increase collaboration with sub-specialists around ... patients. --> Sectra (STO: SECT ... entered into a multi-year agreement to provide Breast Imaging ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone will experience death ... or animal pass away, death lives among us. It is your perspective, however, that ... family of 11 children, author T Sky understands that she may see death more ...
(Date:11/30/2015)... ... November 30, 2015 , ... Sikka Software announced today that ... Their Ecosystem empowers dentists to make complex business decisions by providing the tools and ... a free fee survey with 10 procedures customized by zip code. , The ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... alliance around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair in ... TIGR® Matrix is a long-term resorbable surgical mesh intended to support and reinforce ...
(Date:11/30/2015)... ... November 30, 2015 , ... SIMmersion’s ability ... to the medical schools of the future. To reach an audience of key ... 2015 ChangeMedEd conference in Chicago, organized by the American Medical Association. , ...
(Date:11/30/2015)... CALIF. (PRWEB) , ... November ... ... ( ), a leading provider of enterprise Time and Attendance/Workforce Management ... status in the Microsoft Partner Program with competencies in the Application Development, ...
Breaking Medicine News(10 mins):